scholarly journals Proteome Based Approach Defines Candidates for Designing a Multitope Vaccine against the Nipah Virus

2021 ◽  
Vol 22 (17) ◽  
pp. 9330 ◽  
Author(s):  
Mohamed A. Soltan ◽  
Muhammad Alaa Eldeen ◽  
Nada Elbassiouny ◽  
Ibrahim Mohamed ◽  
Dalia A. El-damasy ◽  
...  
Keyword(s):  
Nipah Virus ◽  
Epitope Prediction ◽  
Dynamics Simulation ◽  
World Health ◽  
Effective Vaccine ◽  
Emerging Viruses ◽  
Glycoprotein G ◽  
Fusion Glycoprotein ◽  
Physicochemical Features ◽  
Health Organization

Nipah virus is one of the most harmful emerging viruses with deadly effects on both humans and animals. Because of the severe outbreaks, in 2018, the World Health Organization focused on the urgent need for the development of effective solutions against the virus. However, up to date, there is no effective vaccine against the Nipah virus in the market. In the current study, the complete proteome of the Nipah virus (nine proteins) was analyzed for the antigenicity score and the virulence role of each protein, where we came up with fusion glycoprotein (F), glycoprotein (G), protein (V), and protein (W) as the candidates for epitope prediction. Following that, the multitope vaccine was designed based on top-ranking CTL, HTL, and BCL epitopes from the selected proteins. We used suitable linkers, adjuvant, and PADRE peptides to finalize the constructed vaccine, which was analyzed for its physicochemical features, antigenicity, toxicity, allergenicity, and solubility. The designed vaccine passed these assessments through computational analysis and, as a final step, we ran a docking analysis between the designed vaccine and TLR-3 and validated the docked complex through molecular dynamics simulation, which estimated a strong binding and supported the nomination of the designed vaccine as a putative solution for Nipah virus. Here, we describe the computational approach for design and analysis of this vaccine.

Critical Insight into the Attributes of Emerging Novel Coronavirus (COVID-19) in India and Across the World

Coronaviruses ◽  
2020 ◽  
Vol 1 (1) ◽  
pp. 49-56
Author(s):  
Gaurav M. Doshi ◽  
Hemen S. Ved ◽  
Ami P. Thakkar
Keyword(s):  
Review Article ◽  
World Health ◽  
Effective Vaccine ◽  
Human Contact ◽  
The World ◽  
Critical Insight ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Insight Into ◽  
Old Drugs

The World Health Organization (WHO) has recently announced the spread of novel coronavirus (nCoV) globally and has declared it a pandemic. The probable source of transmission of the virus, which is from animal to human and human to human contact, has been established. As per the statistics reported by the WHO on 11th April 2020, data has shown that more than sixteen lakh confirmed cases have been identified globally. The reported cases related to nCoV in India have been rising substantially. The review article discusses the characteristics of nCoV in detail with the probability of potentially effective old drugs that may inhibit the virus. The research may further emphasize and draw the attention of the world towards the development of an effective vaccine as well as alternative therapies. Moreover, the article will help to bridge the gap between the new researchers since it’s the current thrust area of research.

scholarly journals A Quantitative and Kinetic Fusion Protein-Triggering Assay Can Discern Distinct Steps in the Nipah Virus Membrane Fusion Cascade

2010 ◽  
Vol 84 (16) ◽  
pp. 8033-8041 ◽  
Author(s):  
Hector C. Aguilar ◽  
Vanessa Aspericueta ◽  
Lindsey R. Robinson ◽  
Karen E. Aanensen ◽  
Benhur Lee
Keyword(s):  
Membrane Fusion ◽  
Receptor Binding ◽  
Nipah Virus ◽  
Heptad Repeat ◽  
Critical Parameters ◽  
Second Phase ◽  
Two Phase ◽  
Glycoprotein G ◽  
Fusion Glycoprotein ◽  
Functional Features

ABSTRACT The deadly paramyxovirus Nipah virus (NiV) contains a fusion glycoprotein (F) with canonical structural and functional features common to its class. Receptor binding to the NiV attachment glycoprotein (G) triggers F to undergo a two-phase conformational cascade: the first phase progresses from a metastable prefusion state to a prehairpin intermediate (PHI), while the second phase is marked by transition from the PHI to the six-helix-bundle hairpin. The PHI can be captured with peptides that mimic F's heptad repeat regions, and here we utilized a NiV heptad repeat peptide to quantify PHI formation and the half-lives (t 1/2) of the first and second fusion cascade phases. We found that ephrinB2 receptor binding to G triggered ∼2-fold more F than that triggered by ephrinB3, consistent with the increased rate and extent of fusion observed with ephrinB2- versus ephrinB3-expressing cells. In addition, for a series of hyper- and hypofusogenic F mutants, we quantified F-triggering capacities and measured the kinetics of their fusion cascade phases. Hyper- and hypofusogenicity can each be manifested through distinct stages of the fusion cascade, giving rise to vastly different half-lives for the first (t 1/2, 1.9 to 7.5 min) or second (t 1/2, 1.5 to 15.6 min) phase. While three mutants had a shorter first phase and a longer second phase than the wild-type protein, one mutant had the opposite phenotype. Thus, our results reveal multiple critical parameters that govern the paramyxovirus fusion cascade, and our assays should help efforts to elucidate other class I membrane fusion processes.

scholarly journals Pharmacotherapeutic management of chronic viral hepatitis

2021 ◽  
Vol 2 (4) ◽  
pp. 1-8
Author(s):  
Gabriela Mitea ◽  
Marius Daniel Radu ◽  
Ana Maria Ionescu ◽  
Nicoleta Blebea
Keyword(s):  
Hepatitis B ◽  
Viral Hepatitis ◽  
World Health Organization ◽  
Geographical Area ◽  
Chronic Viral Hepatitis ◽  
World Health ◽  
Effective Vaccine ◽  
Special Importance ◽  
The World ◽  
Health Organization

In infectious diseases, viral hepatitis has an increased incidence, being an important cause of morbidity and mortality, being a "sentinel" indicator of the socio-economic and hygienic-cultural standard of a geographical area. The World Health Organization (WHO) admits the following types of hepatitis viruses: A, B, B + D, C, E, F and G. Among the viral entities recognized by the WHO, a special importance in terms of incidence, evolution over time with the risk of chronicity and the therapeutic options are presented by hepatitis B and C. There is currently an effective vaccine as well as treatment for hepatitis B. There is no vaccine for hepatitis C, but in recent years considerable progress has been made in treating this disease. Also, the introduction of drugs known as direct-acting antivirals makes it possible to cure over 90% of patients within 2-3 months. But in many countries, current drug policies, regulations and prices keep treatment out of the reach of most people with hepatitis. Eradication of viral hepatitis is possible if greater emphasis is placed on prevention, diagnosis and treatment. Vaccination is very important, as it is possible for types A and B of hepatitis. Early diagnosis is also extremely important, given that there are currently very effective drugs that can prevent the development of liver cancer. The WHO also noted that about two million people worldwide become ill each year due to the reuse of syringes and stressed the importance of checking blood donors to see if they are not carriers of hepatitis B or C viruses. Therefore, the purpose of this article is to highlight the pharmacological treatment and the main therapeutic and prevention schemes currently used for patients with these liver diseases. The paper was based on the most popular methods of identification of the latest international information about the treatment of hepatitis (by electronic search using Pubmed, SciFinder, Scirus, GoogleScholar and Web of Science). We also consulted the global literature cited in the hepatitis database of the World Health Organization (WHO) updated frequent from the current literature on this topic.

Hepatitis Viruses: Oysters, Blood Transfusions, and Cancer

2020 ◽  
pp. 187-200
Author(s):  
Michael B. A. Oldstone
Keyword(s):  
Virus Infection ◽  
Hepatitis Virus ◽  
Chinese Literature ◽  
Fourth Century ◽  
World Health ◽  
Effective Vaccine ◽  
Hepatitis Viruses ◽  
Hbv Vaccine ◽  
Health Organization ◽  
The Ancient Chinese

This chapter studies the history of hepatitis virus infection. Hepatitis and/or jaundice were recorded in the fourth century BC by Hippocrates and over 1,000 years ago in the ancient Chinese literature. By the end of the nineteenth century and early twentieth century, the association of a virus infection with jaundice and liver disease was made. The major hepatitis viruses are hepatitis A (HAV), hepatitis B (HBV), and non-A, non-B or hepatitis C (HCV). HAV is transmitted almost always by fecal–oral routes but occasionally by transfusion or inoculation of blood obtained during the transient stage of viremia that occurs during the HAV incubation period. While there is currently no effective vaccine for HCV, an effective vaccine exists for HBV. A problem with the HBV vaccine is individuals refusing to be vaccinated. Nevertheless, recent progress made on the understanding and treatment of these viruses has led to the World Health Organization planning that by 2030 hepatitis infections will be reduced by 90% and deaths by 65%.

scholarly journals Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity

2019 ◽  
Vol 7 (8) ◽  
pp. 255 ◽  
Author(s):  
Stewart ◽  
Triccas ◽  
Petrovsky
Keyword(s):  
Infectious Agent ◽  
Mechanisms Of Action ◽  
Clinical Development ◽  
World Health ◽  
Effective Vaccine ◽  
Bacillus Calmette Guerin ◽  
Mycobacterium Tuberculosis Infection ◽  
Future Directions ◽  
Vaccine Protection ◽  
Health Organization

Tuberculosis (TB) caused by Mycobacterium tuberculosis infection is responsible for the most deaths by a single infectious agent worldwide, with 1.6 million deaths in 2017 alone. The World Health Organization, through its “End TB” strategy, aims to reduce TB deaths by 95% by 2035. In order to reach this goal, a more effective vaccine than the Bacillus Calmette-Guerin (BCG) vaccine currently in use is needed. Subunit TB vaccines are ideal candidates, because they can be used as booster vaccinations for individuals who have already received BCG and would also be safer for use in immunocompromised individuals in whom BCG is contraindicated. However, subunit TB vaccines will almost certainly require formulation with a potent adjuvant. As the correlates of vaccine protection against TB are currently unclear, there are a variety of adjuvants currently being used in TB vaccines in preclinical and clinical development. This review describes the various adjuvants in use in TB vaccines, their effectiveness, and their proposed mechanisms of action. Notably, adjuvants with less inflammatory and reactogenic profiles that can be administered safely via mucosal routes, may have the biggest impact on future directions in TB vaccine design.

scholarly journals Poliovirus-nonsusceptible Vero cell line for the World Health Organization global action plan

2020 ◽  
Author(s):  
Yuko Okemoto-Nakamura ◽  
Kenji Someya ◽  
Toshiyuki Yamaji ◽  
Kyoko Saito ◽  
Makoto Takeda ◽  
...  
Keyword(s):  
Vero Cell ◽  
World Health Organization ◽  
Action Plan ◽  
World Health ◽  
Emerging Viruses ◽  
Polio Vaccination ◽  
The World ◽  
Global Action ◽  
Health Organization ◽  
Global Action Plan

AbstractPolio or poliomyelitis is a disabling and life-threatening disease caused by poliovirus (PV). As a consequence of global polio vaccination efforts, wild PV serotype 2 has been eradicated, and wild PV serotypes 1- and 3-transmitted cases have been largely eliminated except for in limited regions around the world. However, vaccine-derived PV, pathogenically reverted live PV vaccine strains in vaccinated humans, has become a serious issue. For the global eradication of polio, the World Health Organization is conducting the third edition of the Global Action Plan, which is requesting stringent control of potentially PV-infected materials. To facilitate the mission, we generated a PV-nonsusceptible Vero cell subline, which may serve as an ideal replacement of standard Vero cells to isolate emerging/re-emerging viruses without the risk of generating PV-infected materials.

scholarly journals Contact tracing: a lesson from the Nipah virus in the time of COVID-19

2020 ◽  
Vol 50 (3) ◽  
pp. 174-175 ◽  
Author(s):  
Arun Wilson ◽  
Anup Warrier ◽  
Balram Rathish
Keyword(s):  
Single Case ◽  
Nipah Virus ◽  
Community Setting ◽  
Healthcare Setting ◽  
Daily Basis ◽  
World Health ◽  
Contact Tracing ◽  
The Public ◽  
Contact List ◽  
Health Organization

Without a vaccine or proven therapeutic options in COVID-19, the World Health Organization (WHO) recommends a combination of measures: rapid diagnosis and immediate isolation of cases; rigorous contact tracing; and precautionary self-isolation of close contacts to curb the spread of COVID-19. During a Nipah outbreak in Kerala, India in 2019, it was confined to a single case. The authors were involved in the in-hospital contact tracing. With a single patient producing a contact list of 98 in a healthcare setting, the implications in a community setting during a pandemic of the scale of COVID-19 are huge but it proves that early and rigorous tracing with quarantining is an effective strategy to limit clusters. We believe that if the public is encouraged to maintain their own contact list on a daily basis, it would help in significantly reducing the time and effort invested into contact tracing in the event of a person contracting COVID-19.

scholarly journals Chlorate formation in water distribution systems: a modeling study

2015 ◽  
Vol 18 (1) ◽  
pp. 115-125 ◽  
Author(s):  
Fulvio Boano ◽  
Silvia Fiore ◽  
Roberto Revelli
Keyword(s):  
Distribution Systems ◽  
Water Distribution ◽  
Treatment Plant ◽  
Water Treatment Plant ◽  
Threshold Value ◽  
Distribution Networks ◽  
World Health ◽  
Guideline Values ◽  
Physicochemical Features ◽  
Health Organization

Chlorine-based disinfection agents are known to favor the production of disinfection by-products (DBPs), whose concentrations are restricted by international guidelines to ensure a safe consumption of drinking water. Hence, it is important to understand the behavior of DBPs within water distribution networks (WDNs) to avoid users' exposure to concentrations higher than guideline values. The build-up in chlorate concentration resulting from chlorinated disinfectants is here simulated with the EPANET 2.0 software for one benchmark WDN serving about 130,000 inhabitants. Chlorate generation was accounted by means of an empirical model, considering different boundary conditions (physicochemical features of raw water, disinfectant dose). The gathered results indicate that increases in chlorate concentration within the considered WDN are narrow. Chlorate neo-formation in the WDN is, however, strictly related to the initial amount of chlorate released by the water treatment plant, i.e., to the input value in the WDN. If chlorate concentration in treatment plants is kept below 700 μg/L (i.e., World Health Organization guideline), depending on the mixing conditions in tanks, the simulation results referred to the considered WDN show that the DBP build-up within the network is limited (in any case lower than 5–7% of the threshold value).

SARS-CoV-2: The Path of Prevention and Control

2020 ◽  
Vol 20 ◽  
Author(s):  
Amal A. Mohamed ◽  
Nouran Mohamed ◽  
Seham Mohamoud ◽  
Fawkia E. Zahran ◽  
Rania Abdelmonem Khattab ◽  
...  
Keyword(s):  
Prevention And Control ◽  
Vaccine Development ◽  
Demographic Data ◽  
World Health ◽  
Effective Vaccine ◽  
Healthy Population ◽  
Food And Agriculture ◽  
Food And Agriculture Organization ◽  
Health Organization ◽  
And Control

: The 2019 coronavirus pandemic (COVID-19) continues to expand worldwide. Although the number of cases and the death rate among children and adolescents are reported to be low compared to adults, limited data have been reported. We urgently need to find treatment and vaccine to stop the epidemic. Vaccine development is in progress, but any approved and effective vaccine for COVID-19 is at least 12 to 18 months. The World Health Organization (WHO), the Center for Disease Control and Prevention (CDC), and the Food and Agriculture Organization (FAO) have issued instructions and strategies for containing COVID-19 outbreak to the general public, physicians, travelers and injured patients to follow so that the transmission to a healthy population can be prevented. In this review, we summarize demographic data, clinical characteristics, complications and outcomes and finally prevention and control of this serious pandemic.

A Review on Prevention, Transmission and Symptoms of the Covid-19

2021 ◽  
Author(s):  
Hamid Mohammadi ◽  
Yahya Ehteshaminia ◽  
Seif Ali Mahdavi
Keyword(s):  
Respiratory Tract ◽  
World Health ◽  
Definitive Treatment ◽  
Effective Vaccine ◽  
Upper Respiratory Tract ◽  
Number Of Patients ◽  
The Face ◽  
History Of ◽  
Health Organization ◽  
Respiratory Droplets

Introduction: Coronavirus belongs to a family of viruses that can cause symptoms such as pneumonia, fever, shortness of breath and lung infection. On December 29, 2019, the World Health Organization (WHO) coined the term New Coronavirus 2019 to refer to a coronavirus that affects the lower respiratory tract of patients with pneumonia in Wuhan, China. The new coronavirus was first identified in Wuhan, among a number of patients with an unknown form of viral pneumonia who also had a history of Huanan seafood market. Materials and Methods: In this study, the websites of PubMed, Google Scholar, SID, and Magiran were searched and related articles were reviewed. Results: Symptoms of COVID-19 occur after a period of 2 to 10 days and the period of symptoms resulting in death of patients varied between 6 to 41 days. Common symptoms at the onset of the disease are fever, cough, and fatigue. Each carrier is reported to infect an average of 3.77 others. Conclusion: Regarding the way of transmission of viral diseases of the upper respiratory tract, such as COVID-19, i.e., the transmission by respiratory droplets as well as close communication between individuals, solutions have been recommended by experts. Researchers are suggesting not touching the T-zone on the face, using a mask and following the principles of social distancing are the most effective ways to control the disease. Due to the lack of definitive treatment or effective vaccine for COVID-19 so far, following these principles has a significant role in combating this pandemic.

Sign in / Sign up

Export Citation Format

Share Document